Optimi Health Corp. (Nasdaq: OPTH), a commercial-stage pharmaceutical company focused on psychedelic drug products, announced the closing of its oversubscribed US$15 million underwritten public offering in connection with its uplisting to the Nasdaq Capital Market. The offering consisted of 2,400,000 common shares priced at US$6.25 per share, with an additional 360,000 share over-allotment option granted to the underwriter.
Lucosky Brookman LLP served as Special Nasdaq Counsel, guiding the Company through the Nasdaq approval process and supporting its successful uplisting. Joseph Gunnar & Co., LLC acted as sole book-running manager for the offering.
